

Statement of Standalone Unaudited Results for the Quarter ended 31.12.2017

(in Rs.)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended	
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
I.	Revenue from operations	25785127	33719949	0	87423921	0
II.	Other income	45882	44371	150000	291133	450000
III.	Total Income (I+II)	25831009	33764320	150000	87715054	450000
IV.	Expenses					
	(a) Cost of materials consumed	16963439	13736054	0	57356065	0
	(b) Purchase of stock-in-trade	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-7268692	6674743	0	-9071580	0
	(d) Employee benefits expense	6574520	6942345	0	18607147	0
	(e) Finance Costs	91962	186881	0	278843	0
	(f) Depreciation and amortisation expense	2615600	2724000	0	7826600	0
	(g) Other expenses	6485151	4601075	183719	15541237	433343
	Total expenses (IV)	25461980	34865098	183719	90538312	433343
V.	Profit/(Loss) from operations before exceptional items and tax (I-IV)	369029	-1100778	-33719	-2823258	16657
VI.	Exceptional Items	0	0	0	0	0
VII.	Profit/ (Loss) before tax (V-VI)	369029	-1100778	-33719	-2823258	16657
VIII.	Tax expense:	0	0	0	0	0
	(1) Current tax	0	0	0	0	0
	(2) Deferred tax	0	0	0	0	0
IX.	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	369029	-1100778	-33719	-2823258	16657
X.	Profit/(loss) from discontinued operations	0	0	0	0	0
XI.	Tax expense of discontinued operations	0	0	0	0	0
XII.	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0
XIII.	Profit (Loss) for the period (IX+XII)	369029	-1100778	-33719	-2823258	16657
XIV.	Other Comprehensive Income					
	A. (i) Items that will not be reclassified to profit or loss					
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss					
	(ii) Income tax relating to items that will be reclassified to profit or loss					
XV.	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	369029	-1100778	-33719	-2823258	16657



XVI	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000
XVII	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):					
	(a) Basic	0.10	-0.29	-0.01	-0.75	0.00
	(b) Diluted					

Notes:

- The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th February, 2018.
- The Statutory Auditors have carried out Limited Review of the Unaudited standalone results for the quarter ended 31st December, 2017
- The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
- Statement of Unaudited Financial Results of the company for the quarter/nine months ended 31st December 2017, in the prescribed format under Schedule III of Companies Act, 2013
- The figures for the previous period have been regrouped wherever necessary.
- The company has opted to avail the relaxations provided by the SEBI, vide its circular no. CIR/CFD/FAC/62/2016 dated 5th July, 2016, as available to listed entities. Accordingly, the company has provided IND AS compliant financial results only for corresponding quarter and nine months ended on 31.12.2016 . Thus, in accordance to the relaxation provided in aforesaid circular by SEBI, the results for the quarter and nine months ended 31st December, 2016 have not been subject to Limited Review or audit. However, management has excersied necessary due deligence to ensure that the financial results provide a true and fair view.
- The company have not submitted Ind-AS compliant financial results for the previous year ended 31st March, 2017 since the same is not mandatory as per SEBI cirular no. CIR/CFD/FAC/62/2016 dated 5th July, 2016.
- The figures stated above for quarter and nine months ended 31st December, 2016 are as per Ind AS and in complete reconciliation with previously applicable GAAP. No difference has been observed between the same. For reference, reconciliation table is provided below:

Reconciliation of Net Profit as previously reported under Indian GAAP to Ind-AS is as under:		
Particulars	Quarter ended 31.12.2016	Nine Months Ended 31.12.2016
Net Profit/Loss as per previous GAAP (IND GAAP)	-33719	16657
Adjustments	Nil	Nil
Net Profit/Loss as per IND AS	-33719	16657

FOR, PARMAX PHARMA LIMITED

Alkesh Gosalia

Alkesh Gosalia
Director



Place: Hadamtala (Rajkot)
Date: 14.02.2018

BHARAT A. SHAH

B.Com. F.C.A. (DISA)

B. A. SHAH ASSOCIATES

Chartered Accountants

209 Sapphire, 2nd Floor, 21/25 – B, New Jagnath Plot, Rajkot. – 360 001. Ph.: 0281 - 2468261

**Auditor's Limited Review Report
On Unaudited Financial Results**

To

**The Board of Directors,
PARMAX PHARMA LIMITED**

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and six months ended 31st December 2017 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on 14th February 2018. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRS:) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B A SHAH ASSOCIATES

Chartered Accountants

FRN.: 109493W

Bharat A Shah

BHARAT SHAH

PROPRIETOR

M. NO.034222



Date: 14.02.2018

Place: Rajkot